All In Biotech

Drug Trial Radar · NCT07240376

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

Efficacy and Safety of Stapokibart (CM310) in Non-Allergic Rhinitis With Eosinophilia Syndrome (ESSNARES): An Investigator-initiated, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Dec 31, 2026

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Renmin Hospital of Wuhan University; Wuhan TongJi Hospital
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310. The main questions it aims to answer are: Does drug CM310 relieve the symptoms of participants? What medical problems do participants have when injecting CM310? Researchers will compare CM310 to a placebo (a look-alike substance that contains no drug) to see if CM310 works to treat NARES. Participants will: Inject CM310 or a placebo every 2 weeks for 12 weeks, and follow up for another 8 weeks. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms every day.

Conditions

  • Non-Allergic Rhinitis With Eosinophilia Syndrome

Interventions

  • Stapokibart (CM310)Biological

    Paticipants were given CM310 (with an initial dose of 600 mg followed by 300mg subcutaneous injection, once every two weeks) for 12 weeks. Follow up for another 8 weeks.During the treatment period, mometasone furoate was sprayed nasal every day

  • PlaceboOther

    After enrollment, paticipants were given a placebo (subcutaneous injection, with the same dose as the experimental group, once every two weeks) for 12 weeks. Follow up for another 8 weeks. During the treatment period, mometasone furoate was sprayed nasal every day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean change from baseline in the Reflective Total Nasal Symptom Score (rTNSS) at Week 12.Time frame: From enrollment to the end of treatment at 12 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Eye & Ent Hospital of Fudan University

    Shanghai, China

  • Clifford Hospital

    Guangzhou, Guangdong, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Tongji hospital, Tongji medical college, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hubei Provincial Hospital of Integrated Chinese and Western Medicine

    Wuhan, Hubei, China

  • The Central Hospital of Wuhan

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.